Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Current Portion
Balance at beginning of period	$ 76.1
Acquisition	0.0
Payments	(84.8)
Reclassifications	58.5
Accretion	0.0
Fair value loss	0.0
Balance at end of period	49.8
Long-Term Portion
Balance at beginning of period	139.0
Acquisition	345.0
Payments	0.0
Reclassifications	(58.5)
Accretion	36.9
Fair value loss	28.4
Balance at end of period	490.8
Total Contingent Consideration
Balance at beginning of period	215.1
Acquisition	345.0
Payments	(84.8)
Reclassifications	0.0
Accretion	36.9
Fair value loss	28.4
Balance at end of period	540.6
Biocon Biologics
Total Contingent Consideration
Balance at beginning of period	$ 15.8